KR970706818A - 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide) - Google Patents

뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)

Info

Publication number
KR970706818A
KR970706818A KR1019970702591A KR19970702591A KR970706818A KR 970706818 A KR970706818 A KR 970706818A KR 1019970702591 A KR1019970702591 A KR 1019970702591A KR 19970702591 A KR19970702591 A KR 19970702591A KR 970706818 A KR970706818 A KR 970706818A
Authority
KR
South Korea
Prior art keywords
neuropeptide
excess
compound
condition associated
rti
Prior art date
Application number
KR1019970702591A
Other languages
English (en)
Inventor
로버트 프레데릭 쥬니어 브런즈
도날드 리차드 젤러트
제임스 제프리 하우버트
윌리암 헨리 워커 룬
Original Assignee
피터 쥐. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 쥐. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 쥐. 스트링거
Publication of KR970706818A publication Critical patent/KR970706818A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

하기 화학식(Ⅰ)의 화합물 또는 그의 제약학적으로 허용되는 염 또는 용매 화합물 유효량을 과량의 뉴로펩티드 Y와 관련된 생리학적 질환 또는 그것의 증상의 억제를 필요로 하는 인간에게 투여하는 것으로 이루어지는, 과량의 뉴로펩티드 Y와 관련된 생리학적 질환 또는 그것의 증상의 억제 방법
상기 식에서, R1및 R3은 각각 수소, -CH3, (a)또는 (b)이고, 여기에서 Ar은 임의로 치환된 페닐이고; R2는 피롤리딘, 헥사메틸렌이미노 및 피페리디노로 이루어지는 군으로부터 선택된다.

Description

뉴로펩티드 Y와 관련된 상태의 억제 방법(METHODS OF INHIBITING CONDITIONS ASSOCIATED WITH NEUROPERTIDE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 유효량의 하기 화학식(Ⅰ)의 화합물 또는 그의 제약학적으로 허용되는 염 또는 용매 화합물을 과량의 뉴로펩티드 Y와 관련된 생리학적 질환의 억제를 필요로 하는 인간에게 투여하는 것으로 이루어지는, 과량의 뉴로펩티드 Y와 관련된 생리학적 질환의 억제 방법.
    상기 식에서, R1및 R3은 각각 수소, -CH3, (a)또는 (b)이고, 여기에서 Ar은 임의로 치환된 페닐이고; R2는 피롤리딘, 헥사메틸렌이미노 및 피페리디노로 이루어지는 군으로부터 선택된다.
  2. 제1항에 있어서, 상기 화합물이 그의 염산염의 방법.
  3. 제1항에 있어서, 상기 투여가 예방을 위한 것인 방법.
  4. 제1항에 있어서, 상기 화합물이 하기 화학식의 화합물 또는 그의 염산염인 방법.
  5. 제1항에 있어서, 과량의 뉴로펩티드 Y와 관련된 상태가 불안인 방법.
  6. 제1항에 있어서, 과량의 뉴로펩티드 Y와 관련된 상태가 비만인 방법.
  7. 제1항에 있어서, 과량의 뉴로펩티드 Y와 관련된 상태가 우울인 방법.
  8. 제1항에 있어서, 과량의 뉴로펩티드 Y와 관련된 상태가 통증 또는 외상 수용인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702591A 1994-10-20 1995-10-19 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide) KR970706818A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/326,675 US6562862B1 (en) 1994-10-20 1994-10-20 Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US08/326,675 1994-10-20
PCT/US1995/013246 WO1996012490A1 (en) 1994-10-20 1995-10-19 Methods of inhibiting conditions associated with neuropeptide y

Publications (1)

Publication Number Publication Date
KR970706818A true KR970706818A (ko) 1997-12-01

Family

ID=23273204

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702591A KR970706818A (ko) 1994-10-20 1995-10-19 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)

Country Status (19)

Country Link
US (5) US6562862B1 (ko)
EP (1) EP0785785A4 (ko)
JP (1) JPH10507757A (ko)
KR (1) KR970706818A (ko)
CN (1) CN1091598C (ko)
AU (1) AU689664B2 (ko)
CA (1) CA2200990A1 (ko)
CZ (1) CZ287411B6 (ko)
FI (1) FI971635A0 (ko)
HU (1) HUT76852A (ko)
IL (1) IL115663A (ko)
MY (1) MY132056A (ko)
NO (1) NO971520L (ko)
NZ (1) NZ295575A (ko)
RU (1) RU2188015C2 (ko)
TW (1) TW410156B (ko)
UA (1) UA46744C2 (ko)
WO (1) WO1996012490A1 (ko)
ZA (1) ZA958800B (ko)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5494929A (en) * 1995-01-12 1996-02-27 Eli Lilly And Company Methods of inhibiting growth hormone effects
US5532254A (en) * 1995-06-07 1996-07-02 Eli Lilly And Company Modulation of calcium channels using benzothiophenes
US5840747A (en) * 1995-06-07 1998-11-24 Eli Lilly And Company Calcium channel antagonists
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
AU730137B2 (en) 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof
US6113876A (en) * 1996-01-29 2000-09-05 Eli Lilly And Company Methods of increasing sphincter competence
CZ235598A3 (cs) * 1996-01-29 1999-03-17 Eli Lilly And Company Derivát 2-fenyl-3-aroylbenzothiofenu nebo jeho farmaceuticky vhodná sůl nebo solvát pro přípravu farmaceutického prostředku ke zvyšování působnosti svěračů
DE69713402T2 (de) 1996-08-23 2002-11-07 Agouron Pharma Liganden des neuropeptids y
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
JP2000510164A (ja) * 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
AU6267198A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amides as npy5 receptor antagonists
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
JP4228398B2 (ja) * 1997-04-23 2009-02-25 萬有製薬株式会社 神経ペプチドｙ受容体拮抗剤
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
DE69830409T2 (de) 1997-08-05 2006-01-26 Pfizer Products Inc., Groton 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten
ATE234098T1 (de) * 1997-08-05 2003-03-15 Pfizer Prod Inc 4-aminopyrrole (3,2-d) pyrimidinen als antagonisten des neuropeptide y receptors
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
AU9105598A (en) * 1997-08-21 1999-03-08 Eli Lilly And Company Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis
AU9106198A (en) * 1997-08-21 1999-03-08 Eli Lilly And Company Methods for inhibiting temporomandibular disorders
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
US20050107327A1 (en) * 1997-12-19 2005-05-19 Hormos Medical Corporation Method for reducing overproduction of neuropeptide Y in an individual
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
GB2344050A (en) * 1998-11-26 2000-05-31 Ferring Bv Agents useful in the treatment of reproductive disorders.
EP1027891B1 (en) * 1999-01-27 2004-12-29 Pfizer Products Inc. Neuropeptide y antagonists
AU2512800A (en) * 1999-02-03 2000-08-25 Eli Lilly And Company Alpha1-adrenergic receptor antagonists
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000066578A1 (en) 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
US6506762B1 (en) 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
WO2001026651A2 (en) * 1999-10-14 2001-04-19 Endorecherche, Inc. Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
WO2001053477A1 (en) * 2000-01-20 2001-07-26 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of neuropeptide y activity
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US6511984B2 (en) 2000-03-30 2003-01-28 Pfizer Inc. Neuropeptide Y antagonists
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
JP2005516001A (ja) 2001-12-05 2005-06-02 ベイラー カレッジ オブ メディスン 交感神経活動状態の調節による骨形成の制御のための方法及び組成物
US6958347B2 (en) * 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
US6949564B2 (en) * 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
JP2004224756A (ja) * 2003-01-24 2004-08-12 Sumika Fine Chemicals Co Ltd ２，６−ジハロゲノ−８−置換−プリン化合物およびその製造方法
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
EP2338490A3 (en) 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
BRPI0507485A (pt) 2004-02-05 2007-07-10 Probiodrug Ag inibidores novos de glutaminil ciclase
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
AU2005237274B2 (en) * 2004-05-04 2011-02-17 Hormos Medical Ltd Novel oral formulations of ospemifene
WO2006050999A2 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
AU2006235200A1 (en) * 2005-04-15 2006-10-19 Regenertech Pty Limited Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5363344B2 (ja) * 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
WO2009071601A1 (en) 2007-12-03 2009-06-11 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
EP3360870A1 (en) * 2013-02-19 2018-08-15 Novartis AG Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4891357A (en) * 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
JPH07502268A (ja) 1991-11-27 1995-03-09 ノボ　ノルディスク　アクティーゼルスカブ 化学化合物、それらの製法および使用
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
ES2105525T3 (es) 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
TW303299B (ko) 1993-07-22 1997-04-21 Lilly Co Eli
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5457113A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5574047A (en) 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
JPH07196494A (ja) 1993-12-21 1995-08-01 Eli Lilly & Co 強迫性障害および消費性障害を抑制するための医薬組成物
US5439931A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5476862A (en) 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression

Also Published As

Publication number Publication date
MX9702853A (es) 1997-07-31
MY132056A (en) 2007-09-28
IL115663A (en) 1999-08-17
CZ115997A3 (en) 1997-10-15
TW410156B (en) 2000-11-01
HUT76852A (en) 1997-12-29
IL115663A0 (en) 1996-01-19
WO1996012490A1 (en) 1996-05-02
US5576337A (en) 1996-11-19
CN1160998A (zh) 1997-10-01
US6562862B1 (en) 2003-05-13
US5504094A (en) 1996-04-02
CN1091598C (zh) 2002-10-02
ZA958800B (en) 1997-04-18
EP0785785A1 (en) 1997-07-30
NO971520D0 (no) 1997-04-03
FI971635A (fi) 1997-04-17
US5567715A (en) 1996-10-22
US5567714A (en) 1996-10-22
CA2200990A1 (en) 1996-05-02
JPH10507757A (ja) 1998-07-28
RU2188015C2 (ru) 2002-08-27
NO971520L (no) 1997-04-03
CZ287411B6 (en) 2000-11-15
EP0785785A4 (en) 1998-11-11
AU689664B2 (en) 1998-04-02
AU3895595A (en) 1996-05-15
NZ295575A (en) 2000-06-23
FI971635A0 (fi) 1997-04-17
UA46744C2 (uk) 2002-06-17

Similar Documents

Publication Publication Date Title
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016744A (ko) 트롬빈을 저해하는 방법
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
RU97108050A (ru) Способ ингибирования состояний, связанных с нейропептидом y
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR950016747A (ko) 여성의 임신 억제방법
KR950016729A (ko) 유방 질환의 억제 방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR970705384A (ko) 골 보철 파손의 억제 방법(methods for inhibiting bone prosthesis degeneration)
KR950016741A (ko) 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application